Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
(AMSC - Get Report)
was initiated with a Neutral rating at Wedbush. $25 price target. Timing of an acceleration in growth remain uncertain, Wedbush said.
Babcock & Wilcox
was upgraded at Goldman Sachs from Neutral to Buy. Stock appears oversold, following its recent pullback, Goldman said.
(DGI - Get Report)
was initiated with a Market Perform rating at Morgan Keegan. Valuation call, based on a $33 price target.
was started with a Buy rating at Collins Stewart. $55 price target. Company will likely ramp Provenge manufacturing capacity to meet customer demand, Collins Stewart said.
(EW - Get Report)
was rated new Hold at Jefferies. Stock appears fully valued at current levels, Jefferies said.
was upgraded at Oppenheimer from Perform to Outperform. $19 price target. Estimates also boosted, as the company has multiple potential acquisition opportunities.
(GVA - Get Report)
was downgraded at Goldman Sachs to Sell. Sentiment remains negative on the civil business, and funding is a concern, Goldman said.
was upgraded at Goldman Sachs to Neutral. Backlog is inflecting, Goldman said.
(MAR - Get Report)
was upgraded at Wells Fargo to Outperform. Valuation call, as it appears that isolated event led to a disappointing first quarter, Wells Fargo said.
was upgraded to Buy at Goldman Sachs. $12.40 price target. Company can cut costs and turn its business around, Goldman said.
was downgraded at UBS from Buy to Neutral. $64.50 price target. Valuation call, as the stock has gained 12% year-to-date, UBS said.
was downgraded at Goldman Sachs from Neutral to Sell. Company has limited exposure to commercial and personal lines, Goldman said.
was upgraded at Goldman Sachs from Sell to Neutral. Consensus estimates appear to low, as pricing should ultimately recover, Goldman said.
was upgraded at Goldman Sachs from Neutral to Buy. Company should see increased pricing, Goldman said.
End of report.